Register for our free email digests:
Division of Samsung Electronics Co. Ltd.
Latest From Samsung BioLogics
Local firm Yuhan is taking over from Merck as marketing partner in South Korea for Samsung Bioepis’ biosimilars amid speculation that weak sales of infliximab and etanercept may have triggered the realignment. Samsung Bioepis and Merck's broader partnership, however, remains intact.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in August 2017.
French biotech expands fibrosis partnership with Boehringer Ingelheim, and a co-development pact with AbbVie around ROR gamma inverse agonists. Helsinn signs on to detail Novartis' Zykadia in the US.
Samsung Bioepis is shifting gears moving into the development of novel biologics via a strategic collaboration with Takeda. The partners will initially focus on acute pancreatitis and jointly develop Takeda's preclinical candidate in the segment.
- Contract Research, Toxicology Testing-CRO
- Therapeutic Areas
- Samsung-Quintiles joint venture
- South Korea
- Pacific Rim
- Parent & Subsidiaries
- Samsung Electronics Co. Ltd.
- Senior Management
Tae Han Kim, PhD, CEO
Dongjoong Kim, CFO
- Contact Info
Phone: 2 2255 8500
300 Songdo Bio Way
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.